article thumbnail

GW’s Cannabis-Based Epilepsy Drug Set For European Approval

Cannabis Law Report

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. GW Pharmaceuticals said in May, Epidiolex was successful in treating seizures in patients with a rare form of childhood epilepsy called tuberous sclerosis complex during a late-stage trial.

article thumbnail

The Week in Weed: November 29, 2019

The Blunt Truth

The state’s Medical Cannabis Advisory Board will consider petitions to allow cannabis use for dogs with epilepsy when they meet next, in December. And speaking of New Mexico, medical marijuana might not be just for humans anymore! In keeping with the holiday spirit, we would like to take a moment to thank you, our readers.

Hemp 79
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Chad West Law Firm Reports On The More Promising Bills From The Texas 2019 Session

Cannabis Law Report

Chad West March 27, 2019. Texas could make meaningful progress on marijuana-related bills by the end of the 2019 legislative session. Currently, only epilepsy patients may use the drug produced at three state facilities. If passed, H.B. Stephanie Klick, R-Fort Worth. If passed, H.B. 2416 – Sen.

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study.

article thumbnail

Insys Development Company, Inc. v. GW Pharma Limited Co., Case No. IPR2017-00503 – PTAB Only Partially Smokes Cannabis Patent

Cannabis Law Report

January 2019. s patent directed to the use of cannabinoids, including cannabidiol (“CBD”), in the treatment of certain types of epilepsy. Sterne, Kessler, Goldstein & Fox P.L.L.C. Eleven of thirteen cannabis patent claims survive PTAB challenge. Insys Development Company, Inc. i] Insys Development Company, Inc. 36 (P.T.A.B.

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

article thumbnail

Answer of the Day for May 7, 2022

TheAnswerPage

American Epilepsy Society (AES): Written Comments to Norman E. Food and Drug Administration (FDA), Department of Health and Human Services (HHS): on Docket ID# FDA-2019-N-1482, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019.